<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062203</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0010</org_study_id>
    <nct_id>NCT02062203</nct_id>
  </id_info>
  <brief_title>Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of single oral therapeutic and
      supratherapeutic doses of AKB-6548 on the QT interval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following AKB-6548 administration.</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline heart rate (HR), PR interval, QRS interval</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers defined as QTcF &gt;450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (ΔQTcF) &gt;30 msec (increased by 30 msec) and &gt;60 msec</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for HR, PR interval, QRS interval</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of T wave morphology changes</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following moxifloxacin administration</measure>
    <time_frame>multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters to include adverse events; changes in routine clinical laboratory measures including chemistry, hematology, and urinalysis; and clinically significant changes noted during physical examinations or in vital signs</measure>
    <time_frame>from first dose of study medication through the final protocol required visit</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AKB-6548 (therapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AKB-6548 (supratherapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-6548 (therapeutic dose)</intervention_name>
    <description>Single oral dose of AKB-6548 at a therapeutic dose level</description>
    <arm_group_label>AKB-6548 (therapeutic dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-6548 (supratherapeutic dose)</intervention_name>
    <description>Single oral dose of AKB-6548 at a supratherapeutic dose level</description>
    <arm_group_label>AKB-6548 (supratherapeutic dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Single oral dose of 400 mg moxifloxacin</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy, non-smoking males or females, 18 and 55 years of age, inclusive

          -  BMI 18.0 and 32.0 kg/m2, inclusive

          -  non clinically significant 12-lead ECG

          -  heart rate of 45 to 90 beats per minute, inclusive

          -  mean systolic blood pressure &lt;141 mmHg and mean diastolic blood pressure &lt; 90 mmHg

        Key Exclusion Criteria:

          -  history or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or psychiatric
             disease

          -  history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias, or
             torsades de pointes, structural heart disease, or a family history of Long QT
             syndrome

          -  significant abnormalities in liver function tests

          -  history of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs

          -  history of Gilbert's Syndrome

          -  positive hepatitis panel

          -  seizure disorder or receiving anti-epilepsy medication for seizure disorder

          -  any acute or chronic condition that, in the opinion of the Investigator, may pose a
             safety risk to a subject in this study or which would limit the subject's ability to
             complete and/or participate in this clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Shalwitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Akebia Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Akebia</keyword>
  <keyword>QT interval</keyword>
  <keyword>TQT</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>chronic renal insufficiency</keyword>
  <keyword>renal impairment</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
